{"id":"NCT00975884","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults","officialTitle":"Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09-14","primaryCompletion":"2010-04-30","completion":"2010-04-30","firstPosted":"2009-09-14","resultsPosted":"2019-01-28","lastUpdate":"2019-03-18"},"enrollment":312,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"GSK investigational vaccine GSK2340272A","otherNames":[]}],"arms":[{"label":"GSK2340272A (D21) GROUP","type":"EXPERIMENTAL"},{"label":"GSK2340272A (M6) GROUP","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.","primaryOutcome":{"measure":"Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies","timeFrame":"At Day 21","effectByArm":[{"arm":"GSK2340272A 18-60 YEARS SUB-GROUP","deltaMin":154,"sd":null},{"arm":"GSK2340272A > 60 YEARS SUB-GROUP","deltaMin":121,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":5,"countries":["France"]},"refs":{"pmids":["22824474"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":184},"commonTop":["Pain","Fatigue","Myalgia","Headache","Arthralgia"]}}